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Cardiac Transplantation with Cyclosporin A and Prednisone 
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Influenced by continuing impro~ement in results from Stanford, 
cardiac transplantation was resumed at the University Health 
Center of Pittsburgh in June 1980. Cyclosporin A (CyA) became 
available to the authors early in 1981. This report describes 
the preliminary experience with 21 patients who were treated 
between March 1981 and April 10, 1982 with cyclosporin A 
and low-dose steroids. Ages ranged from eight to S3 years, 
median 46 years. :\ledian age of ten patients disabled because 
of idiopathic myocardiopathy was 33 years; it was 4S years 
in the 11 suffering from ischemic heart disease. Sixteen of the 
21 patients survived. Eleven have survived for three months, of 
which six have survived for six months, giving a cumulative 
survival of 74 and 66%, respectively. Four died perioperatively; 
one died at six weeks and one at four months. Hyperacute 
rejection resulted in one death at 12 hours even though the 
warm and cold Iymphocytotoxic crossmatch for T and 8 cells 
was negative as evaluated by try pan blue. The two late deaths 
were related to infection. No late death has occurred because 
of rejection, and a unique feature is that three recipients with 
a Iymphocytotoxic mismatch did not develop hyperacute re-
jection. The number of infectious episodes and nonviral infec-
tions appears to be less than that associated with the use of 
azathiaprine and larger doses of steroids. Cyclosporin A (5-10 
mg/kg/d) and low-dose prednisone (rapidly tapered in seven 
days from 200 mg to 15-20 mg/d) is effective in preventing 
early morbid rejection of the transplanted heart. 
I NFLUENCED BY THE continuing improvement in re-
sults reported from Stanford, 1.2 the authors resumed 
cardiac transplantation in June 1980. Cyclosporin A 
(CyA) became available to the authors in Pittsburgh 
early in 1981. At that time there was evidence that 
significantly better results could be obtained with CyA 
than with azathiaprine (Aza) for transplantation of 
kidneys and livers. 3- 5 A randomized trial of CyA vs. 
conventional treatment with Aza for renal transplan-
tation was underway at the University Health Center 
of Pittsburgh, and CyA was the agent used routinely 
with hepatic transplantation. With this background 
CyA with steroids, but without other immunosuppres-
sive drugs. was adopted as the routine immunosup-
pressive agent. This report describes preliminary ex-
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perience with 21 patients who were treated between 
March 1981 and April 10, 1982 with Cyclosporin A 
and steroids. 
Patient Selection 
Most of the 21 patients selected for transplantation 
met the criteria described by Baumgartner et al. 2 All 
were NYHA Class IV. Ages ranged from eight to 53 
years. median 46 years. Median age of ten patients 
disabled because of idiopathic cardiomyopathy was 33 
years; it was 45 years in the II suffering from ischemic 
heart disease. Seven patients were receiving inotropic 
drugs intravenously on admission to the hospital, ven· 
tilation was assisted in three, and two were on balloon 
assist devices. Three patients could be weaned from the 
drip or assist device before operation. 
ABO blood type was compatible in all cases. Com-
patibility of donor lymphocytes with recipient serum 
was desired and was evaluated in all cases. In three 
cases in which the donor heart was procured from a 
distant city, a positive T and B, warm and cold. mis-
match against donar lymphocytes was first known dur-
ing implantation of the donor heart. More recently 
serum of the recipient has been sent to the location of 
the donor, and compatibility determined before removal 
of the recipient's heart. 
Immunosuppression 
Cyclosporin A has been given orally just before op-
eration. An intravenous preparation has been available 
since December 1981, but in some hemodynamically 
unstable patients. this has caused hypotension. and it 
is now used only in case of great urgency. Initially the 
dosage schedule that had been developed with renal 
transplantation of 17.5 mg/kg/d was usedK~ Becausl! 
of oliguria soon after operation. which did not seem 
related to the operation. the dose was reduced. and the 
usual dose at present is 10 mg/kg/d. When given in-
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travenously, 40% of this dose was used. Because of el-
evation of serum creatinine in five patients, bilirubin in 
two, and both in two additional patients, the CyA dose 
was reduced from 10 mg/kg/d and averaged 8 mg/kg/ 
d (range 4-10 mg/kg/d) in the 13 patients discharged 
from the hospital. 
Previous experience with steroid drugs and Cy A sug-
gested that large initial doses could be rapidly tapered 
to low maintenance levels, thereby avoiding some of the 
morbid side effects of steroids.4•5 The authors' practice 
reflects aiming for this goal. One g of methylprednisone 
has been given as the aorta was released and circulation 
restored to the donor heart during transplantation. 
Prednisone, 200 mg/d, in two divided doses was started 
after operation, and the daily dose was reduced by 20 
mg each day to a maintenance level of 15 to 20 mg 
daily. If oral medication was not possible, an equivalent 
dose of methylprednisone was given intravenously. Be-
cause of its short duration of action, hydrocortisone, 1 
g intravenously, was used to combat rejection, usually 
without alteration of the course of prednisone. The 
number and frequency of pulses was varied depending 
upon the degree of rejection as determined by clinical 
signs, or more commonly, by endomyocardial biopsy 
(Table 1). 
In case of severe acute rejection, three daily doses of 
hydrocortisone were given. For less severe rejection, the 
pulsed doses were given at three-, five-, or seven-day 
intervals. The last regimen, that is, three doses of hy-
drocortisone at weekly intervals, was used for outpa-
tients with mild histologic evidence of rejection. 
In one instance of severe, acute rejection, in addition 
to three daily doses of hydrocortisone, the daily oral 
dose of prednisone was restored to 200 mg and subse-
quently reduced over the following five days to the 
original maintenance level (Fig. I). 
The amount of drugs was adjusted to the surface area 
of the eight-year-old patient. Antithymocyte globulin 
has not been used in this series of patients. 
Operative Technique and Donor Procurement 
In all cases orthotopic cardiac transplantation was 
performed utilizing the techniques described by Lower 
and ShumwayY The method of preservation of the 
donor heart varied with respect to the use of cardio-
plegic solution. All grafts were immediatly immersed 
and transported in a 4 C crystalloid solution. Most do-
nor hearts were perfused with 650 to 1000 ml of Stan-
ford cardioplegic solution (4 C) before cardiectomy, 
and recently, additional doses of blood cardioplegia 
have been given during implantation. The latter method 
has been associated with a lesser need for postoperative 
inotropic support. 
TABLE I. Immunosuppression Protocol for CyA 
and Lo ..... ·dose Prednisone 
IMMUNE SUPPRESSION-----.... 
CYCLOSPORIN A 
MAXIMAL DOSE TOLERATED 
Eo_f~~epoticl 
5 -12 -17. 5 mo/ko/d 
STEROIDS 
INITIAL 
Methylprednisolone I 0'" 
MAINTENANCE 
Prednisone 
PULSE 
200 "'9/d 
","0 d 
15-20 "'9/d 
HydrocorlisoM I Om 
Donor referrals have been to the Transplant Organ 
Procurement Foundation of the University of Pitts-
burgh. Thirteen patients received donor hearts procured 
from a distant city and the median transport time was 
112 minutes (range 75-131 minutes). To this was added 
the median 61 minutes of implantation from arrival of 
the heart to release of the aortic clamp. 
Results 
Mortality 
Sixteen of the 21 patients survived during the period 
of study. Eleven have survived for three months, of 
which six have survived for six months, giving a cu-
mulative survival of 74 and 66%, respectively (Fig. 2). 
Four patients died perioperatively; one died at six weeks 
and one at four months. 
Hyperacute rejection resulted in one death at 12 
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FIG. I. Immunotherapy plus hemodynamic and biopsy findings in one 
patient with early severe rejection. Cy A was discontinued pcriopcr-
atively because of renal toxicity. 
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FIG. 2. Actuarial survival curve for all patients treated from March 
1981 to April 1982. 
hours even though the warm and cold Iymphocytotoxic 
crossmatch for T and B cells was negative as evaluated 
by trypan blue. This patient had had a PRA (percentage 
reactive antibodies) that varied from 30 to 100% while 
awaiting transplantation. Myocytolysis, arterioles con-
taining IgM and fibrinogen, and sludging of red blood 
cells in the capillaries was interpreted as hyperacute 
rejection. Two patients died of multiple complications 
related to severe cerebral infarctions. One of these had 
nearly recovered from a cerebral embolus that had oc-
curred one week before transplantation. Following the 
operation, he never regained normal cerebral function. 
The second had been supported with diastolic augmen-
tation and large amounts of inotropic drugs for two 
weeks before transplantation. At operation there was 
thrombus attached to the ascending aortic wall. An 
uneventful convalescence was interrupted by a cerebral 
embolus that resulted in a neurologically related death. 
Extensive thrombus was present in the distal ascending 
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FIG. 3. Grades of histologic changes noted on endomyocardial biopsy 
specimens In 15 patients. 
aorta and beyond. In the fourth case, a small donor 
heart never generated an adequate cardiac output When 
transplanted into an adult with pulmonary hyperten-
sion. 
The two late deaths were related to infection, bac-
teroides peritonitis of an inexplicable source, and cy-
tomegalic pneumonia with an associated enterobacter-
mediastinal abscess. 
Rejection 
Endomyocardial biopsies obtained with the Caves-
Schultz Stanford bioptome provided a morphologic in-
dex of rejection as defined by Billingham.7 Mild and 
moderate histologic evidence of rejection is common 
during the initial six weeks following transplantation 
(Fig. 3). When Cy A was reduced to less than 5 mg/ 
kg/d, two patients had severe histologic evidence of 
rejection, one of which was associated with a moderate 
fall in blood pressure and one with severe congestive 
heart failure and hypotension (Fig. I). These episodes 
resolved over two weeks following increases in the CyA 
dose and pulse therapy with hydrocortisone. At four 
weeks and again at six months after transplantation, 
severe histologic rejection was found in another patient. 
The early episode was,not accompanied by clinical signs 
and occurred with a Cy A dose of 17.5 mg/kg/d. The 
late rejection was associated with moderate congestive 
heart failure with a dose of CyA of 6 mg/kg/d and 
prednisone of 20 mg/d. Each of these episodes was re-
versed through the use of pulse therapy. 
Two of three recipients survived despite having Iym-
phocytotoxic antibodies to the donor's lymphocytes by 
two-color immunofluorescence technique with ethidium 
bromide. Within the first six weeks, both had moderate 
histologic rejection and mild cardiac failure. The first 
died at six weeks of infection after having received more 
pulse therapy, due to the authors' special concern, than 
would have been administered had the mismatch not 
been present. The second, alive two months later, was 
treated without consideration of the mismatch and on 
the basis of biopsies. At two weeks, moderate deposition 
of IgM in the arterioles was correlated with moderate 
histologic rejection. Both findings resolved at two 
months-no IgM, mild histologic rejection.s 
The third patient who had lymphocytotoxic antibod-
ies to the donor's lymphocytes died 30 hours after op-
eration of low cardiac output (the fourth case referred 
to previously under mortality). This recipient had re-
ceived a small donor heart and had moderately elevated 
pulmonary vascular resistance preoperatively (7 Wood 
units). The heart had minimal deposition of IgM and 
fibrinogen without red cell sludging, and so the findings 
were inconsistent with hyperacute rejection (Table 2), 
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Biopsies of all recipients treated with Cy A and low-
dose prednisone have a scattered, focal, fine, interstitial 
fibrosis that becomes evident within two weeks whether 
or Dot acute rejection has occurred (Fig. 4), Scattered, 
focal interstitial mononuclear cells are common and do 
not portend rejection. A moderate amount of myocar-
dial fibrosis has been evident following episodes of re-
jection. 
Infection 
, Infectious episodes have been monitored by the Oi-I vision of Infectious Diseases. In addition to the first 14 
cardiac recipients, this experience includes information 
on patients receiving a primary renal transplant who 
were randomized to treatment with Aza, II patients, 
or CyA, 15 patients, and 18 patients receiving a second 
renal transplant and treated with CyA9 (Table 3). 
The fraction of patients developing one or more in-
fections was highest in the primary renal Aza group 
(91%) and less in the CyA renal (67%) and cardiac 
(70%) groups. These differences are not statistically 
.1 aigoificant. The mean number of infectious episodes per 
I patient was also highest in the primary renal Aza group 
TABLE. 2. Summary of Findings of Biopsy and Autopsy Specimens 
in Four Patients with Positive Warm T and B Cell Crossmatches 
LYMPHOCYTOTOXIC CROSSMATCH---..... 
POSITIVE 
POSITIVE 
NEGATIVE" 
POSITIVE 
~ 
+/-
+/-
++ 
Fib 
+1-
.+++ 
+ 
SLUDGE OUTCOME 
LIVED 6WK 
ALIVE 2MO 
++~+ DEAD 1210iR 
DEAD 30HR 
(2.4/patient). Nonviral infections were highest in the 
primary renal Aza group (1.5/patient) compared with 
the CyA renal (0.5/patient) and cardiac (0.9/patient) 
groups. The differences in infectious episodes and non-
viral infections per patient are all significant (p < 0.05). 
Twenty infectious episodes occurred in II of the 14 
cardiac patients on CyA. Eight pulmonary infections 
in six patients was the leading site, compared with three 
cutaneous in three, one urinary tract in one, five gas-
FIG. 4. Endomyocardial biopsy specimen demonstrating interstitial fibrosis (hematoxylin-eosin. X 170). 
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TABLE. 3. Infectious Episodes Noted in Randomized Aza vs. CyA 
Renal Transplant Trial and in 14 Patients Receiving CyA 
Following Cardiac Transplantation 
INFECTIOUS EPISODES------_. 
AZA CyA CyA 
RENAL RENAL CARDIAC 
INFECTED/ TOTAL 91% 67% 70% 
NUMBER/PATI ENT 24 09 14 
NON-VIRAL/PATIENT I 5 05 09 
n = II n = 3:3 n= 14 
I------------------------~ 
trointestinal-peritoneal in four, and three other sites in 
two patients. 
Twenty-one isolates in 11 patients included five gram-
negative aerobes in five patients and four gram-positive 
organisms in three. Among the latter, there was one 
staphylococcus isolate in one patient, and 13 nonstaphy-
lococcus organisms in II. One fungal (Aspergillus) 
isolate occurred in one patient. 
CyA Adverse Reactions 
Diastolic hypertension has been present in II of 13 
patients discharged from the hospital and tends to begin 
within the first postoperative week. It has developed 
irrespective of preoperative hypertension or measurable 
postoperative CyA renal toxicity. The observed hyper-
tension has been difficult to control with diuretics and 
peripheral vasodilators. While studies are incomplete, 
the hypertension appears atypical in that the usual sleep 
related fall in diastolic pressure is not observed. 
Hirsutism has occurred in all surviving patients and 
has been a cosmetic concern in the two adult female 
recipients. A fine tremor of the upper extremities and 
nasal congestion have been transient. Hyperplasia of 
the gums has occurred rarely, is dose related, and con-
sidered to be a manifestation of overdosage. A number 
of patients have been troubled after operation by gas-
trointestinal ileus resulting in abdominal distension 
which has required nasogastric drainage and cathartics. 
Discussion 
Following cardiac transplantation, immunosuppres-
sion is effective with CyA (5-\0 mg/kg/d) and low-
dose prednisone (rapidly tapered in seven days from 200 
mg to \5-20 mg/d). Endomyocardial biopsy has been 
the primary index of rejection used to manage immu-
nosuppression. Neither electrocardiographic voltage 
(summation of leads I, II. III. VI and V6 ) nor arrhyth-
mia has been reliably predictive of rejection. In the first 
six weeks, mild to moderate histologic rejection is com-
mon, but it usually is not associated with functional 
impairment of the graft or recipient. Pulse therapy with 
hydrocortisone alone is effective in reversing rejection. 
The single death attributed to rejection, which was hy-
peracute, occurred in a patient who matched on Iym-
phocytotoxic testing by trypan blue. This test may be 
inadequately sensitive because on another occasion try-
pan blue failed to detect Iymphocytotoxicity that was 
evident by two-color immunofluorescence with ethidium 
bromide. Especially in the presence of a high PRA, the 
latter technique should be used. A unique feature of 
this series is that three recipients with a Iymphocyto-
toxic mismatch did not develop hyperacute rejection. 
Two patients have died of infection, one at six weeks, 
and one at four months. Although the series is small 
and we have not had sufficient experience with cardiac 
transplants treated with Aza for a meaningful com-
parison from our own experience, experience with other 
organs at this institution has shown a lesser incidence 
of bacterial infection than that which occurred with 
Aza and steroids. The fraction of patients developing 
one or more infections, the mean number of infectious 
episodes per patient, and the mean number of nonviral 
infections is less than in patients who are treated with 
Aza. No predisposition for staphylococcal or fungal 
isolates is evident. 
Factors related to selection of recipients and donors 
caused as many deaths, all perioperative, as did rejec-
tion and infection together. The two patients dying of 
neurologically-related causes would now not be trans-
planted; a small heart would now not be used for a large 
recipient, especially one with high pulmonary vascular 
resistance. None of these deaths reflects on CyA and 
low-dose prednisone as the immunosuppressive agent. 
Preoperative use of CyA in amounts of 17.5 mg/kg 
is associated with an inordinately high incidence of post-
operative oliguria whereas 10 mg/kg is less so, and the 
latter is currently the authors' loading dose. Renal tox-
icity mandates frequent monitoring and readjustment 
of maintenance doses, especially in the first several days 
after operation. Special caution is necessary should the 
amount be less than 5 mg/kg/d, and, should it be nec-
essary to discontinue CyA for longer than 24 hours, 
Aza should be used temporarily. It is always possible 
to resume the use of CyA at a dose that is therapeutic 
and yet not toxic. 
Hepatic toxicity does occur but is much less common 
than renal toxicity. [t infrequently necessitates manip-
ulation of the dose and never discontinuance of CyA 
for cardiac transplantation. 
Hirsutism, upper extremity tremors, gastrointestinal 
ileus and constipation, hyperplasia of the gums, and 
- ----- .. _----------------, 
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nasal congestion are nuisances. Hypertension in these 
patients is a new experience and presumably is related 
to CyA as it has developed in patients who were pre-
viously normotensive. It has been difficult to treat. 
Conclusion 
CyA and low-dose prednisone are effective in pre-
venting early morbid rejection of the transplanted heart, 
and may be superior in that the number of infectious 
episodes and non viral infections appears to be less than 
tbat associated with the use of Aza and larger doses of 
steroids. 
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ripheral T-cell values and also the use of electrocardiographic criteria 
are far less valuable, 
DR. BARTLEY P. GRIFFITH (Closing discussion): We used Cyclos-
porin A for immunosuppression in the eight-year-old girl who received 
an orthotopic transplant. While the oncogenic properties of Cyclos-
porin A may become an especially significant problem for youthful 
recipients. we believed that the known problems associated with the 
use of prednisone at doses of I to 0.5 mgjkgjday impose a known 
substantial morbidity, We feel that lower doses of prednisone and 
Cyclosporin A may be a better alternative. 
Renal toxicity associated with cardiac transplantation and Cyclos-
porin A has been common. and at times a difficult problem. We have 
made a strong effort to keep our immunosuppressant regimen of Cy-
c1osporin A and low-dose prednisone pure and thus have not routinely 
substituted for Cyclosporin A. We are quick to decrease Cyclosporin 
A to doses of 5 mg/kg/day if urine output falls. hyperkalemia occurs. 
and if creatinine rises abruptly. In a few patients we have discontinued 
Cyclosporin A for 12 hours. In one patient. Cyclosporin A was dis-
continued for 24 hours. and aggressive rejection occurred. If this sit-
uation were to occur again. we would substitute Azothiaprine after 
24 hours. 
Conventionally. electrocardiographic voltage. T-cell rosettes. and 
endomyocardial biopsy have been used for the detection of graft re-
jection, In the Cyclosporin A group. the changes in electrocardiograph 
voltage frequently did not precede or even mirror marked histologic 
changes evident in the endomyocardial biopsy. This may. in part. be 
due to the presence of less myocardial edema observed In Cyclosporin 
A-treated patients. Because rabbit antithymocyte has not been used 
in our series. T-cell rosettes have remained elevated and did nOI change 
in any observable pattern during a rejection episode. Recently. we 
have measured peripheral T-cell helper and suppressor ratio. but 
changes in the ratio have not correlated with histologic or clinical 
rejection. The endomyocardial biopsy has been obtained routinely at 
weekly intervals for the first four weeks following transplantation and. 
therefore. as the clinical situation may dictate, The results of the 
biopsy have directed the use of pulse therapy with steriods. 
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